Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of Serplulimab (HLX10) + HLX04 in Advanced Solid Tumors
NCT03757936Phase 1Unknown
- Sponsor
- Henlius
- Start
- Nov 2018
- Primary completion
- Sep 2019
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of serplulimab in solid tumor (advanced stage), sponsored by Henlius. Primary endpoints: Maximum Tolerated Dose at 28 days and Dose Limiting Toxicity at 28 days. Status: unknown.
02
Drugs
serplulimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03757936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03757936.